Ilyang Pharmaceutical Co Ltd (007575) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ilyang Pharmaceutical Co Ltd (007575) has a cash flow conversion efficiency ratio of 0.009x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.26 Billion ≈ $1.53 Million USD) by net assets (₩239.41 Billion ≈ $162.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Ilyang Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Ilyang Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Ilyang Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ilyang Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ilyang Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bogazici Beton Sanayi ve Ticaret AS
IS:BOBET
|
0.087x |
|
EGH Acquisition Corp. Class A Ordinary Shares
NASDAQ:EGHA
|
-0.002x |
|
Ifishdeco PT
JK:IFSH
|
0.057x |
|
DIRECTA SIM SPA
F:ZP7
|
N/A |
|
UmweltBank AG
XETRA:UBK
|
-0.132x |
|
Pro-Dex Inc
NASDAQ:PDEX
|
0.086x |
|
Unisys Corporation
NYSE:UIS
|
-0.133x |
|
Dekpol SA
WAR:DEK
|
0.076x |
Annual Cash Flow Conversion Efficiency for Ilyang Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Ilyang Pharmaceutical Co Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Ilyang Pharmaceutical Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩241.58 Billion ≈ $163.71 Million |
₩5.61 Billion ≈ $3.81 Million |
0.023x | -68.77% |
| 2023-12-31 | ₩196.41 Billion ≈ $133.10 Million |
₩14.62 Billion ≈ $9.91 Million |
0.074x | -27.43% |
| 2022-12-31 | ₩291.85 Billion ≈ $197.79 Million |
₩29.94 Billion ≈ $20.29 Million |
0.103x | -58.41% |
| 2021-12-31 | ₩271.76 Billion ≈ $184.17 Million |
₩67.02 Billion ≈ $45.42 Million |
0.247x | +5.08% |
| 2020-12-31 | ₩244.92 Billion ≈ $165.98 Million |
₩57.48 Billion ≈ $38.96 Million |
0.235x | +44.44% |
| 2019-12-31 | ₩222.74 Billion ≈ $150.95 Million |
₩36.19 Billion ≈ $24.53 Million |
0.162x | +54.17% |
| 2018-12-31 | ₩209.88 Billion ≈ $142.23 Million |
₩22.12 Billion ≈ $14.99 Million |
0.105x | -25.94% |
| 2017-12-31 | ₩210.98 Billion ≈ $142.98 Million |
₩30.03 Billion ≈ $20.35 Million |
0.142x | +14.64% |
| 2016-12-31 | ₩217.35 Billion ≈ $147.30 Million |
₩26.98 Billion ≈ $18.29 Million |
0.124x | -34.96% |
| 2015-12-31 | ₩211.00 Billion ≈ $142.99 Million |
₩40.27 Billion ≈ $27.29 Million |
0.191x | +87.97% |
| 2014-12-31 | ₩183.46 Billion ≈ $124.33 Million |
₩18.63 Billion ≈ $12.62 Million |
0.102x | -- |
About Ilyang Pharmaceutical Co Ltd
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more